Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Hims & Hers launches compounded semaglutide pill as lower-cost weight loss option Published: 12:08 05 Feb 2026 EST Hims & Hers (NYSE:HIMS) has announced the launch of a compounded semaglutide pill designed for weight loss, providing an alternative to Novo Nordisk (NYSE:NVO)s Wegovy
BPC-157 has been studied for its potential to reduce systemic inflammation, providing relief from pain and discomfort while enhancing overall mobility and well-being
When will the medication start to work
2 The FDA approval of Wegovy HD is based on the results of the STEP UP trial program, which included STEP UP, a 72-week study which evaluated the efficacy and safety of once-weekly Wegovy 7.2 mg compared to placebo and Wegovy 2.4 mg, as an adjunct to lifestyle intervention in 1,407 adults with obesity (BMI 30 kg/m 2 or greater), without diabetes
